OrthoPediatrics (NASDAQ:KIDS) Upgraded at Truist Financial

OrthoPediatrics (NASDAQ:KIDS) was upgraded by analysts at Truist Financial to a “hold” rating in a report issued on Thursday, Zacks reports.

Several other equities analysts have also recently issued reports on KIDS. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. BTIG Research restated a “buy” rating and issued a $29.00 price target on shares of OrthoPediatrics in a research report on Monday, September 14th. Needham & Company LLC lifted their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Finally, Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Stock Down 2.6%

KIDS stock opened at $21.69 on Thursday. The company has a market cap of $566.33 million, a P/E ratio of -12.91 and a beta of 0.99. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $26.74. The company’s 50-day moving average price is $22.76 and its 200 day moving average price is $19.50. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, research analysts expect that OrthoPediatrics will post -1.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, Director David R. Pelizzon sold 302,369 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the director directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Jennifer N. Pritzker sold 302,369 shares of OrthoPediatrics stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the insider owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,100,000 shares of company stock worth $46,747,931. 32.50% of the stock is owned by corporate insiders.

Institutional Trading of OrthoPediatrics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Waverly Advisors LLC boosted its stake in shares of OrthoPediatrics by 6.7% in the second quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock valued at $237,000 after purchasing an additional 775 shares during the period. Legal & General Group Plc purchased a new stake in OrthoPediatrics during the 2nd quarter worth $34,000. Quantinno Capital Management LP acquired a new position in OrthoPediatrics in the 1st quarter worth $160,000. R Squared Ltd acquired a new position in OrthoPediatrics in the 1st quarter worth $212,000. Finally, Bank of America Corp DE purchased a new position in OrthoPediatrics in the 2nd quarter valued at about $268,000. 69.05% of the stock is owned by hedge funds and other institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.